Who are Reuterin D3 drops's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Probiotics(VSL#3), Ganeden BC30, Synbiotic 2000, Bifidobacterium Bifidum Oral Capsule, Mesalazine plus Lactobacillus casei, Lactobacillus plantarum.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/reuterin-d3-drops.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Reuterin D3 drops — Competitive Intelligence Brief

Reuterin D3 drops (Reuterin D3 drops) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Probiotic. Area: Gastroenterology.

phase 3 Probiotic Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Reuterin D3 drops (Reuterin D3 drops) — University of Campania Luigi Vanvitelli. Reuterin D3 drops is a probiotic supplement that contains a combination of beneficial bacteria and vitamin D3.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Reuterin D3 drops TARGET	Reuterin D3 drops	University of Campania Luigi Vanvitelli	phase 3	Probiotic
Probiotics(VSL#3)	Probiotics(VSL#3)	Govind Ballabh Pant Hospital	marketed	Probiotic
Ganeden BC30	Ganeden BC30	Massachusetts General Hospital	marketed	Probiotic
Synbiotic 2000	Synbiotic 2000	Beth Israel Medical Center	marketed	Synbiotic (prebiotic + probiotic combination)
Bifidobacterium Bifidum Oral Capsule	Bifidobacterium Bifidum Oral Capsule	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	marketed	Probiotic
Mesalazine plus Lactobacillus casei	Mesalazine plus Lactobacillus casei	Hospital Cristo Re	marketed	Anti-inflammatory agent plus probiotic combination
Lactobacillus plantarum	Lactobacillus plantarum	Shenzhen People's Hospital	marketed	Probiotic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Probiotic class)

BioBalance Corporation · 1 drug in this class
Biocodex · 1 drug in this class
CD Pharma India Pvt. Ltd. · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
Chuncheon Sacred Heart Hospital · 1 drug in this class
Dow University of Health Sciences · 1 drug in this class
Federico II University · 1 drug in this class
Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan · 1 drug in this class
GWT-TUD GmbH · 1 drug in this class
Aga Khan University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Reuterin D3 drops — Competitive Intelligence Brief. https://druglandscape.com/ci/reuterin-d3-drops. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab